We are live on ! Find out more
ZVSA

ZyVersa Therapeutics
ZVSA

Delisted

ZVSA was delisted on the 16th of July, 2025.

Back to rankings

9 hedge funds and large institutions have $73.4K invested in ZyVersa Therapeutics in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

80% more funds holding

Funds holding: 5 → 9 (+4)

0% less ownership

Funds ownership: 0% → 0% (-0%)

73% less capital invested

Capital invested by funds: $273K → $73.4K (-$200K)

Holders
9
Holders Change
+4
Holders Change %
+80%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$90.3K
2
CAC
Cowen and Company
New York
+$37.5K
3
TSS
Two Sigma Securities
New York
+$29.7K
4
CSS
Cubist Systematic Strategies
Connecticut
+$27.6K
5
SG
StoneX Group
New York
+$9.45K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$200K
2
UBS Group
UBS Group
Switzerland
-$6.33K

ZVSA Hedge Fund Activity: Q2 2023 in Review

9 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q2 2023, worth a combined $73.4K — down 73% from $273K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ZVSA positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $90.3K. The largest seller was Goldman Sachs, exiting entirely with an estimated $200K sold.

  • 9 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q2 2023, up from 5 in Q1 2023.
  • Funds reported $73.4K of ZyVersa Therapeutics stock for Q2 2023, down 73% quarter-over-quarter.
  • 6 funds opened new ZyVersa Therapeutics positions in Q2 2023 and 2 closed out, a net change of +4 holders.
  • The largest ZyVersa Therapeutics buyer in Q2 2023 was Virtu Financial, an estimated $90.3K added.
  • The largest ZyVersa Therapeutics seller in Q2 2023 was Goldman Sachs, an estimated $200K sold.

Based on aggregated 13F filings for Q2 2023.